Literature DB >> 6205790

Bee keepers' IgG and IgE antibody responses to bee venom studied by means of crossed radioimmunoelectrophoresis.

S L Nordvall, T Uhlin, R Einarsson, S G Johansson, S Ohman.   

Abstract

The immune response to honey bee venom in thirty-seven bee keepers' sera was studied by several methods. Specific IgE antibody levels studied by RAST were generally low, whereas specific IgG antibody levels studied by a Sepharose protein A technique were high. Crossed radioimmunoelectrophoresis was applied for a detailed analysis of the antibody specificities towards the different components of venom in seventeen of the bee keepers' sera. Significant amounts of IgG antibodies were found towards most bee-venom components. The highest IgG response was directed towards phospholipase A. Hyaluronidase, acid phosphatase and two uncharacterized antigens also showed distinct IgG binding. The IgG binding to melittin was low. The IgE binding to the bee venom components was low and primarily directed to the phospholipase. IgE binding to hyaluronidase and acid phosphatase occurred, but was also in very small amounts. One bee-keeper serum caused heavy radiostaining to melittin but the others did not show IgE binding to this component. Thus a low IgE but a high IgG response was demonstrated in bee keepers. The major immunogen was phospholipase A, which is known to be the major allergen in bee venom. Generally, the strongest IgG responses were found to the components capable of inducing the strongest IgE responses.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6205790     DOI: 10.1111/j.1365-2222.1984.tb02214.x

Source DB:  PubMed          Journal:  Clin Allergy        ISSN: 0009-9090


  2 in total

1.  Hymenoptera stings and serum venom-specific IgE in Japanese Pest-control operators.

Authors:  T Ono; M Yoshida; N Nakazono
Journal:  Environ Health Prev Med       Date:  1998-01       Impact factor: 3.674

2.  Molecularly targeted nanocarriers deliver the cytolytic peptide melittin specifically to tumor cells in mice, reducing tumor growth.

Authors:  Neelesh R Soman; Steven L Baldwin; Grace Hu; Jon N Marsh; Gregory M Lanza; John E Heuser; Jeffrey M Arbeit; Samuel A Wickline; Paul H Schlesinger
Journal:  J Clin Invest       Date:  2009-08-10       Impact factor: 14.808

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.